We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ENGS:NASDAQEnergys Group Limited Analysis

Data as of 2026-06-17 - not real-time

$1.99

Latest Price

8/10Risk

Risk Level: High

Executive Summary

ENGS trades at $1.99, above its 20‑day SMA (1.62) and 50‑day SMA (1.41) but still well under the 200‑day SMA (2.63), indicating short‑term momentum but long‑term weakness. RSI 76 signals the stock is in overbought territory, and while the MACD line sits marginally above its signal (bullish), the histogram is thin, suggesting limited upside. The DCF‑derived fair value of $0.40 is less than one‑quarter of the current price, and the price‑to‑book ratio of 14× vastly exceeds the book value of $0.14 per share, pointing to significant overvaluation. Revenue has collapsed by 43% YoY and margins are deeply negative (gross 20%, operating –67%), underscoring fragile fundamentals. Moreover, the company carries a staggering debt‑to‑equity of 429, with total debt of $6.4 M dwarfing its $4.2 M cash pile.
Volatility is extreme, with a 30‑day swing of 82% and a historic max drawdown of nearly 95%, while beta of 0.68 indicates modest correlation to the market but does not offset the price volatility. Trading volume is trending down, and liquidity is modest given a market cap of $62 M and average daily volume around 380 k shares, raising concerns for larger position entries. The firm does not pay a dividend, and with zero earnings per share, dividend sustainability is moot. Geographic exposure to the UK and Hong Kong introduces currency risk, and the waste‑management niche adds sector‑specific regulatory uncertainty. In sum, the technical picture shows fleeting bullish cues, but the fundamental and valuation metrics paint a picture of high risk and limited upside.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • RSI in overbought territory
  • price above short‑term SMAs but below long‑term SMA
  • extreme 30‑day volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • persistent negative earnings and margins
  • high debt‑to‑equity ratio
  • potential upside from project pipeline if cash flow improves

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • DCF fair value far below market price
  • unsustainable leverage and zero dividend
  • historical max drawdown near 95%

Key Metrics & Analysis

Financial Health

Revenue Growth-43.20%
Profit Margin-30.11%
ROA-11.34%
Debt/Equity428.77
P/B Ratio14.1
Op. Cash Flow$-499782
Free Cash Flow$1.1M
Industry P/E31.2

Technical Analysis

TrendNeutral
RSI76.1
Support$1.39
Resistance$2.04
MA 20$1.62
MA 50$1.41
MA 200$2.63
MACDBullish
VolumeDecreasing
Fear & Greed Index92.48

Valuation

Fair Value$0.40
GradeOvervalued
TypeValue

Risk Assessment

Beta0.68
Volatility82.24%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.